Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.

Antibody-labeled gold nanoparticles represent a promising novel tool regarding cancer imaging and therapy. Nevertheless, the characterization of biodistribution of such immunonanocarriers has been poorly documented. In this study, the biodistribution of (89)Zr-labeled cetuximab before and after the coupling reaction to gold nanoparticles (AuNPs) was compared and the quantitative imaging performance of (89)Zr immuno-PET was evaluated. Cetuximab was functionalized with the desferal moiety and labeled with (89)Zr ((89)Zr-Df-Bz-NCS-cetuximab). AuNPs with a mean diameter of 5 nm were synthesized according a new method developed in the laboratory, and conjugated to (89)Zr-Df-Bz-NCS-cetuximab using carbodiimide chemistry (AuNPs-PPAA-cetuximab-(89)Zr). The two tracers were injected in A431 xenograft-bearing mice. Tumor and liver uptakes were assessed at different times after injection using quantitative PET imaging. The in vivo specificity of the binding was investigated using a saturating dose of unlabeled cetuximab. Radiolabeled cetuximab was conjugated to AuNPs with a coupling reaction yield >75%. All conjugates were stable in vitro and to a lesser extent in plasma. In vivo distribution studies revealed no significant difference in tumor uptake for cetuximab conjugated to nanoparticles up to 72 h after injection, compared with unconjugated cetuximab. Immuno-PET studies showed that AuNPs-PPAA-cetuximab-(89)Zr provided high tumor-to-background ratio. The liver uptake of AuNPs-PPAA-cetuximab-(89)Zr was higher, compared with (89)Zr-Df-Bz-NCS-cetuximab. In vivo blocking experiments demonstrated selective tumor targeting after coupling reaction. This study showed that the conjugation of AuNPs to cetuximab did not affect its tumor accumulation and that the efficacy of EGFR-targeted nanoparticles was unaltered. The (89)Zr-labeled cetuximab-targeted gold nanoparticles could be a valuable tool for theranostic purposes.

[1]  Michele Follen,et al.  Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. , 2003, Cancer research.

[2]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[3]  Jason S. Lewis,et al.  Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.

[4]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[5]  Shaker A Mousa,et al.  Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. , 2010, Pharmacology & therapeutics.

[6]  G. V. van Dongen,et al.  (89)Zr-labeled compounds for PET imaging guided personalized therapy. , 2011, Drug discovery today. Technologies.

[7]  G. Denardo,et al.  Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. , 1995, Cancer research.

[8]  S. Curley,et al.  Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. , 2010, Surgery.

[9]  J. Mealey.  Turn-over of Carrier-free Zirconium-89 in Man , 1957, Nature.

[10]  F. Fay,et al.  Antibody-targeted nanoparticles for cancer therapy. , 2011, Immunotherapy.

[11]  Marc C. Huisman,et al.  Performance evaluation of the Philips MOSAIC small animal PET scanner , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Bernard Gallez,et al.  Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: an in vitro and in vivo study , 2012 .

[13]  Johan R de Jong,et al.  Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.

[14]  O. Feron,et al.  PVD Synthesis and Transfer into Water-Based Solutions of Functionalized Gold Nanoparticles , 2009 .

[15]  M. Olivo,et al.  Molecular contrast of EGFR expression using gold nanoparticles as a reflectance-based imaging probe. , 2008, Molecular and cellular probes.

[16]  R. Boellaard,et al.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Coenen,et al.  A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of 88Zr and 89Zr in proton induced reactions on yttrium , 2007 .

[18]  R. Wong,et al.  Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer , 2010, Current oncology.

[19]  R. Mehra,et al.  The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer , 2010, Biologics : targets & therapy.

[20]  P. Jurek,et al.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.

[21]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[22]  R. Boellaard,et al.  Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients , 2006, Clinical Cancer Research.

[23]  O. Feron,et al.  Antibody immobilization on gold nanoparticles coated layer-by-layer with polyelectrolytes , 2011 .

[24]  Judith E. Flores,et al.  Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. , 2010, Nuclear medicine and biology.

[25]  S. Singh,et al.  Functionalized Gold Nanoparticles and Their Biomedical Applications , 2011, Nanomaterials.

[26]  G. Snow,et al.  Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Stanislav Emelianov,et al.  Molecular specific optoacoustic imaging with plasmonic nanoparticles. , 2007, Optics express.

[28]  John Mendelsohn,et al.  Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.

[29]  Keishiro Tomoda,et al.  Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. , 2008, Colloids and surfaces. B, Biointerfaces.

[30]  Xiaohua Huang,et al.  Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. , 2006, Cancer letters.

[31]  Xiaohua Huang,et al.  Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. , 2005, Nano letters.

[32]  D. Abou,et al.  In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.

[33]  Ronald Boellaard,et al.  Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients , 2009, Journal of Nuclear Medicine.

[34]  H. Haisma,et al.  Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  A. Tsourkas,et al.  Comparative Analysis of Nanoparticle-Antibody Conjugations: Carbodiimide Versus Click Chemistry , 2009, Molecular imaging.

[36]  Yin Zhang,et al.  Positron emission tomography imaging of CD105 expression during tumor angiogenesis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.